Momelotinib
Momelotinib is listed in the FDA National Drug Code directory with 7 NDC codes, marketed under brand name including Ojjaara. Available dosage forms: powder, tablet.
Drug Details
- Generic Name
- Momelotinib
- Brand Names
- Ojjaara
- Application Number
- NDA216873
- Sponsor
- Lonza AG
- NDC Codes
- 7
- Dosage Forms
- POWDER, TABLET
- Routes
- ORAL
- Active Ingredients
- MOMELOTINIB, MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE
Indications and Usage
1 INDICATIONS AND USAGE OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia. OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia. ( 1 )